37results about How to "Increase efficacy" patented technology

The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having α-folate receptor (FRα) binding domain and 4-1BB (CD137) costimulatory domain to treat ovarian cancer.

Controlled-release dosage forms containing an opioid agonist; an opioid antagonist; and a controlled release material release during a dosing interval an analgesic or sub-analgesic amount of the opioid agonist along with an amount of said opioid antagonist effective to attenuate a side effect of said opioid agonist. The dosage form provides analgesia for at least about 8 hours when administered to human patients. In other embodiments, the dose of antagonist released during the dosing interval enhances the analgesic potency of the opioid agonist.

Improved procedures for cardiopulmonary resuscitation of a victim of cardiac arrest are provided. In the resuscitation, the victim's chest is mechanically compressed and decompressed to stimulate the heart. The victim is induced to inspire and expire against insufflating breathing gas during the chest compression/decompressions. The breathing gases are adduced under pressure to promote the development of a positive coronary perfusion pressure.

Electro-stimulation of the heart can be carried after positive coronary perfusion pressures have been achieved. The electro-stimulation can be defibrillation or heart pacing or both. The chest compression/decompression cycles and the electro-stimulation measures are synchronized to promote sufficiently body circulation of oxygenated blood in a subject suffering from cardiac arrest. Medical equipment systems are provided for implementing the CPR procedures.

Systems and methods provide for automated, cyclic delivery and evacuation of a treatment or irrigation solution from a tooth root pulp chamber and pulp canals. A manifold has a base member sized and configured to rest on a crown of an instrumented tooth and a top member sized and configured to couple with the base member to define an inlet chamber and an outlet chamber. The distal end of a needle is passed through an opening between the inlet and outlet chambers and extended distally beyond the base member into a pulp canal. The proximal end of the needle includes an opening in fluid communication with the inlet chamber. A solution is transferred from a fluid supply source to the inlet chamber and through the needle into the pulp chamber and pulp canals. The spent solution is evacuated from the pulp chamber and pulp canals through the outlet chamber. The system further includes additional devices, such as a light source, an electrical source, a heat source, for increasing the efficacy of the system.

Food cooking appliance comprising: a centrifugal turbine arranged to create an air flow inside a cooking space, a steam extraction window arranged so as to extract, toward the exterior of the appliance, steam present inside the cooking space, wherein the extraction window has, at every point on its passageway surface, a normal direction with at least one non-zero component along a tangential direction to a circle centered on the centrifugal turbine and passing to the center of the extraction window.

A method and apparatus for increased hitting efficacy in a sporting implement. Energy absorption characteristics are adjusted so as to vary over the hitting surface of the sporting implement. This may be employed to equalize the hitting performance of the sporting implement with respect to different locations of impact thereon.

The disclosed invention generally relates to pharmaceutical and nutraceutical compounds and methods for reducing inflammation, muscle spasms, and pain associated with cancer, trauma, medical procedure, neurological diseases and disorders, as well as other conditions in subjects in need thereof. The disclosed invention further relates to Mitragyna speciose and Cannabis sativa-based compounds and synthetic analogs of the alkaloids found in said plants, where said compounds can also contain a pharmacologically inactive substance for modifying certain qualities of said compounds.

A process is provided for regenerating an exhaust gas after-treatment device in an exhaust line of an internal combustion engine arrangement, the exhaust line including a particle filter. The process includes identifying when soot loading of the particle filter exceeds a predetermined level. After that, temperature of exhaust gases at the particle filter is maintained within a first temperature range until at least one of a predetermined period of time has lapsed or a determination is made that soot loading of the particle filter is below the predetermined level. After that, the temperature of the exhaust gases at the particle filter is increased to within a second temperature range above the first temperature range. An internal combustion engine arrangement is also disclosed.

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism's reaction to the introduction of the medical device to the organism. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned.

Methods of treating an autoimmune disease, an atopic disease, transplantion rejection or GVHD or ameliorating one or more symptoms thereof involves the use of a combination therapy. The therapy involves administering to a subject an extracorporeal photopheresis and a TNF α antagonist.

A device is provided for covering and/or protecting at least one part of the outer surface of a human or animal body. Such a device includes at least one fixed portion for cooling at least one region of the part of the outer surface of the body, able to be refrigerated and/or frozen, and presenting at least three layers arranged in the following order: a breathable layer intended to be applied on and/or near the region; a flexible cold storage and restitution layer; and a heat insulation layer, intended to delay heating of the cold storage and restitution layer.

The invention provides a hydrophilic inclusion complex consisting essentially of nanosized particles of salicylic acid wrapped in an amphiphilic polymer, wherein said amphiphilic polymer is selected from the group consisting of polyacrylic acid, polyacrylamide and copolymers thereof, polymethacrylamide and copolymers thereof, and polylysine, and said amphiphilic polymer is modified by reaction with urea or a derivative thereof, nicotinamide or guanidine. Further provided are hydrophilic dispersions comprising nanoparticles of said inclusion complexes and pharmaceutical and cosmetic compositions comprising said dispersions.

The current invention relates to a process for increasing the efficacy of cancerous disease inhibiting therapeutic agents delivered to a treatment region of a tissue structure, such as a tumor. The multi-step procedure takes advantage of the resulting thermal stress response occurring as a result of exposure to the cold. Coordinating the thermal related stress response with the timing of cancerous disease inhibiting agent action provides a unique therapeutic regiment to treat tumors which provides a maximized effect on the tumor, protects normal cells, and activates local pro-inflammatory cells.

Provided is a functional, low-profile intercranial device (LID). The LID includes a base portion; at least one cavity associated with the base portion and configured to accept at least one functional component; and at least one conduit having a first end in communication with the at least one cavity. The at least one functional component includes a medicinal, electronic, or optic therapeutic. The at least one conduit is configured to accept the medicinal therapeutic and a second end configured to dispense the therapeutic.

Presented is a therapeutic method to treat prostate carcinomas in mammals comprising the administration of cellular PAcP protein. Also presented is a method to diagnose androgen-insensitive prostate carcinomas by determining the expression level of cellular PAcP in the prostate carcinomas, a decrease in expression being indicative of androgen-insensitivity. A promoter region that is specifically expressed in prostate tissue is presented, as is a xenograft animal mode that mimics human prostate carcinomas in the expression of cellular PAcP.

A satellite deorbiting device including an aerobraking surface including a satellite attitude control device with gravity gradient, the device with gravity gradient including at least one mast carrying the aerobraking surface, a first end of which is secured to the satellite and the second end of which is provided with a mass, such that the mast is oriented in a direction opposing that of the planet around which the satellite orbits.

The invention provides improved compositions for adoptive immune effector cell therapies for treatment, prevention, or amelioration of numerous conditions including, but not limited to cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency.

In the field of coding/decoding in telecommunications networks, an error correcting decoder and associated decoding method are adapted to a mesh network.

In particular, the system for the decoding of a plurality of coded copies of a data word includes at least a first decoding stage with:

• • a plurality of soft decision decoders, each decoder being arranged for decoding a coded copy received as decoder input, and
  • a graph-based decoder comprising a plurality of nodes, each node of said graph-based decoder receiving the soft output value from a corresponding decoder and the graph-based decoder determining a decoding value of said data word on the basis of said soft output values.

The present invention concerns methods for assessing the sensibility of a subject to an anticancer treatment, for screening compounds which are useful for treating a cancer and for determining the likelihood of a metastatic relapse in a subject. The methods are based on the finding that a non-functional P2X7-elicited NALP3 inflammasome pathway in a subject is indicative of a resistance to treatment. The invention further concerns methods for treating a cancer and for restoring the sensitivity of the subject to a cancer treatment.

Efficient sequence specific gene silencing is possible through the use of RNAi technology. By selecting particular RNAi molecules by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of RNAi molecules are disclosed including those directed to nucleotide sequences for CNTD2.

The invention provides a lighting device for providing light, the lighting device comprising a closed chamber with a light transmissive window and a light source configured to provide light source radiation into the chamber, wherein the chamber further encloses a wavelength converter configured to convert at least part of the light source radiation into wavelength converter light, wherein the light transmissive window is transmissive for the wavelength converter light, wherein the wavelength converter comprises luminescent quantum dots which upon excitation with at least part of the light source radiation generate at least part of the wavelength converter light, and wherein the closed chamber comprises a filling gas comprising one or more of helium gas, hydrogen gas, nitrogen gas or oxygen gas, the filling gas having a relative humidity at 19° C. of at least 5%.

The invention relates to methods and compositions for the selection of patients for therapy with an anti-inflammatory drug. More particularly, the invention relates to compositions comprising folate-imaging agent conjugates for the selection of patients for therapy with an anti-inflammatory drug, and methods and uses therefor.

Described is a product containing at least one lysophospholipid and at least one fatty acid, as a combined preparation for simultaneous, separate or sequential use, to be topically applied, in order to temporarily and reversibly inhibit a neuromuscular junction or the release of acetylcholine from autonomic nerve endings; this product can be used for treating hyperhidrosis conditions and for the cosmetic treatment of facial and other body wrinkles and, in general, human syndromes caused by the hyperactivity of peripheral nerve terminals.

The present invention relates to a bifunctional molecule comprising an anti-PD-1 antibody and SIRPa and its uses.

The invention discloses a novel pesticide device, which comprises a stirring base body fixedly installed in a moving car body and a spraying base body installed at upside of the stirring base body ina lifting matching manner; a stirring cavity and a dovetail cavity connected to the upside of the stirring cavity are arranged in the inner wall body of the stirring base body, and a dovetail block isglidingly installed in the dovetail cavity; a first thread rod is adaptively installed in the dovetail block by threads, and the extending tail end at the right side of the first thread rod is rotationally and adaptively connected to the inner wall at the right side of the dovetail cavity; the extending tail end at the left side of the first thread rod is adaptively connected with the first motorby power, the outer surface of the first motor is fixedly arranged in the left side inner wall of the dovetail cavity; a second motor is fixedly installed in the lower end face of the dovetail blockat the lower side of the first thread rod, the bottom end of the second motor is adaptively equipped with a stirring shaft extended downwards by power, and the periphery of the outer surface of the stirring shaft is fixedly provided with multiple groups of stirring blades.

The subject invention provides materials and methods for preventing, inhibiting or reducing biofilm formation and biofilm infections in subjects. The materials and methods utilize chlorhexidine, which has been found to be surprisingly non-toxic. The lack of toxicity facilitates the use of chlorhexidine in contexts that were not previously thought to be possible.

An anti-microbial composition including: a solvent; a cationic active ingredient; a source of zinc ions, wherein the zinc ions have a concentration from 6.2×10⁻⁴ to 8.7×10⁻³ mol/L; and an amine oxide surfactant. A method of selectively killing Gram-positive bacteria, the method including: exposing bacteria to a formulation including: 0.05 to 0.3 wt. % of benzethonium chloride and/or benzalkonium chloride; a source of zinc ions, wherein the zinc ions have a concentration from 6.8×10⁻³ to 2×10⁻² mol/L; and an amine oxide surfactant.

The present invention relates to: compositions for modulating the expression of FOXO1 and/or ETV6, the composition comprising one or more intermediate non-coding RNA regulators; attenuating splicing factor expression, the composition comprising an expression modulator of FOXO1 and/or ETV6; attenuating cell senescence and/or re-entry to cell cycle, the composition comprising an expression modulator of FOXO1 and/or ETV6 or their downstream targets related to splicing factor expression; or a composition capable of modulating splicing factor expression, the composition comprising one or more compounds able to bind to, or inhibit, FOXO1 and/or ETV6 genes or their downstream targets related to splicing factor expression. Such compositions have therapeutic benefits in the prevention, management, amelioration or treatment of an age-related disease or condition or cancer or also as a research tool/reagent.

The invention provides combination therapy for use in treating a bacterial biofilm in a subject comprising (a) a polypeptide having serine protease activity and (b) one or more antibiotic compounds. Also provided are compositions and methods of use of the same.